A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients

Hilal D Maradit Kremers, Donnie P. Funch, Richard A. Robson, Michael A. Nalesnik, Shah Ebrahim, Michael J. Cecka, Gerhard Opelz, Nancy A. Dreyer, Alexander M. Walker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant, indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. During the European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk of PTLD in comparison with alternate immunosuppressive regimens. In response, F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology. Copyright (C) 1999 John Wiley and Sons, Ltd.

Original languageEnglish (US)
Pages (from-to)509-518
Number of pages10
JournalPharmacoepidemiology and Drug Safety
Volume8
Issue number7
DOIs
StatePublished - Dec 1999
Externally publishedYes

Fingerprint

Mycophenolic Acid
Lymphoproliferative Disorders
Immunosuppressive Agents
Transplants
Kidney
Lip Neoplasms
Kidney Transplantation
Immunosuppression
Observational Studies
Case-Control Studies
Neoplasms
Cohort Studies
Skin
Pharmaceutical Preparations

Keywords

  • Immunosuppression
  • Mycophenolate mofetil
  • Pharmacoepidemiology
  • Posttransplant lymphoproliferative disorders
  • PTLD
  • Transplantation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. / Maradit Kremers, Hilal D; Funch, Donnie P.; Robson, Richard A.; Nalesnik, Michael A.; Ebrahim, Shah; Cecka, Michael J.; Opelz, Gerhard; Dreyer, Nancy A.; Walker, Alexander M.

In: Pharmacoepidemiology and Drug Safety, Vol. 8, No. 7, 12.1999, p. 509-518.

Research output: Contribution to journalArticle

Maradit Kremers, Hilal D ; Funch, Donnie P. ; Robson, Richard A. ; Nalesnik, Michael A. ; Ebrahim, Shah ; Cecka, Michael J. ; Opelz, Gerhard ; Dreyer, Nancy A. ; Walker, Alexander M. / A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. In: Pharmacoepidemiology and Drug Safety. 1999 ; Vol. 8, No. 7. pp. 509-518.
@article{c2c81b96324d4b5783883846a363bee6,
title = "A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients",
abstract = "Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant, indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. During the European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk of PTLD in comparison with alternate immunosuppressive regimens. In response, F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology. Copyright (C) 1999 John Wiley and Sons, Ltd.",
keywords = "Immunosuppression, Mycophenolate mofetil, Pharmacoepidemiology, Posttransplant lymphoproliferative disorders, PTLD, Transplantation",
author = "{Maradit Kremers}, {Hilal D} and Funch, {Donnie P.} and Robson, {Richard A.} and Nalesnik, {Michael A.} and Shah Ebrahim and Cecka, {Michael J.} and Gerhard Opelz and Dreyer, {Nancy A.} and Walker, {Alexander M.}",
year = "1999",
month = "12",
doi = "10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1",
language = "English (US)",
volume = "8",
pages = "509--518",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients

AU - Maradit Kremers, Hilal D

AU - Funch, Donnie P.

AU - Robson, Richard A.

AU - Nalesnik, Michael A.

AU - Ebrahim, Shah

AU - Cecka, Michael J.

AU - Opelz, Gerhard

AU - Dreyer, Nancy A.

AU - Walker, Alexander M.

PY - 1999/12

Y1 - 1999/12

N2 - Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant, indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. During the European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk of PTLD in comparison with alternate immunosuppressive regimens. In response, F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology. Copyright (C) 1999 John Wiley and Sons, Ltd.

AB - Renal transplant recipients who are chronically immunosuppressed by drugs are at a higher risk of developing malignancies. Commonly observed malignancies are several forms of posttransplant lymphoproliferative disorders (PTLD), skin, lip and gynaecological cancers. The risk is associated with many risk factors including the extent of immunosuppression. Mycophenolate mofetil (MMF) is an immunosuppressant, indicated for the prophylaxis of organ rejection in patients receiving allogenic renal and heart transplants. During the European approval of MMF for renal transplantation, the question was raised as to whether the use of MMF was associated with an increased risk of PTLD in comparison with alternate immunosuppressive regimens. In response, F. Hoffman-La Roche Ltd set up a prospective observational cohort study with a companion case-control study. This paper describes the objectives and the methods of these studies along with the rationale of the methodology. Copyright (C) 1999 John Wiley and Sons, Ltd.

KW - Immunosuppression

KW - Mycophenolate mofetil

KW - Pharmacoepidemiology

KW - Posttransplant lymphoproliferative disorders

KW - PTLD

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0033367137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033367137&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1

DO - 10.1002/(SICI)1099-1557(199912)8:7<509::AID-PDS457>3.0.CO;2-1

M3 - Article

VL - 8

SP - 509

EP - 518

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 7

ER -